I. Zubizarreta

发表

MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis

Dimitris E. Messinis, G. Silberberg, J. Tegnér, 2019, Proceedings of the National Academy of Sciences.

Knowledge Retrieval from PubMed Abstracts and Electronic Medical Records with the Multiple Sclerosis Ontology

H. Mevissen, M. Hofmann-Apitius, E. Kotelnikova, 2015, PloS one.

The analysis of semantic networks in multiple sclerosis identifies preferential damage of long-range connectivity.

J. Sepulcre, J. García-Ojalvo, I. Zubizarreta, 2015, Multiple sclerosis and related disorders.

Precision medicine for multiple sclerosis: an update of the available biomarkers and their use in therapeutic decision making

I. Zubizarreta, I. Pulido-Valdeolivas, P. Villoslada, 2017 .

Dynamics of retinal injury after acute optic neuritis

I. Zubizarreta, P. Villoslada, M. Andorrà, 2015, Annals of neurology.

Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis

N. Bargalló, I. Zubizarreta, I. Pulido-Valdeolivas, 2018, NeuroImage: Clinical.

Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials

I. Zubizarreta, P. Villoslada, R. Cabezón, 2018, Front. Immunol..

Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation

E. Giralt, L. Steinman, I. Pertsovskaya, 2019, Neurotherapeutics.

Systems medicine modeling for multiple sclerosis

E. Kotelnikova, I. Zubizarreta, I. Pulido-Valdeolivas, 2017 .

Total Cerebral Blood Flow in Patients with Cardioembolic Stroke: Is It Clinically Meaningful?

I. Zubizarreta, R. Delgado-Mederos, J. Martí-Fàbregas, 2016, Ultrasound in medicine & biology.

Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.

I. Zubizarreta, I. Pulido-Valdeolivas, C. Montejo, 2019, Multiple sclerosis and related disorders.

Early retinal atrophy predicts long-term visual impairment after acute optic neuritis

I. Zubizarreta, I. Pulido-Valdeolivas, P. Villoslada, 2017, Multiple sclerosis.

Workflow Times and Outcomes in Patients Triaged for a Suspected Severe Stroke

Juan B. Gómez, J. C. Molina, Jose Carlos Molina, 2022, Annals of neurology.

The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS

I. Zubizarreta, P. Villoslada, E. Martínez-Heras, 2014, BMC Research Notes.

Metabolomic signatures associated with disease severity in multiple sclerosis

X. Montalban, E. Kotelnikova, I. Zubizarreta, 2017, Neurology: Neuroimmunology & Neuroinflammation.

Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years

Kunio Nakamura, I. Zubizarreta, I. Pulido-Valdeolivas, 2020, Scientific Reports.

Dynamics and heterogeneity of brain damage in multiple sclerosis

Roland Martin, Pablo Villoslada, Jesper Tegnér, 2017, PLoS Comput. Biol..

Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial

M. Juan, L. Steinman, G. Vilà, 2019, Proceedings of the National Academy of Sciences.

Recommendations for the coordination of Neurology and Neuroradiology Departments in the management of patients with multiple sclerosis.

À. Rovira, I. Zubizarreta, S. Llufriu, 2021, Neurologia.

Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation

E. Giralt, L. Steinman, I. Pertsovskaya, 2019, Neurotherapeutics.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

Alexander Klistorner, Pablo Villoslada, Shiv Saidha, 2016, The Lancet Neurology.

Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability

I. Zubizarreta, I. Pulido-Valdeolivas, P. Villoslada, 2021, Multiple sclerosis.

Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.

I. Zubizarreta, I. Pulido-Valdeolivas, P. Villoslada, 2020, JAMA neurology.

Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis

Sara Llufriu, Pablo Villoslada, Elena H. Martinez-Lapiscina, 2018, JAMA neurology.

Predictors of vision impairment in Multiple Sclerosis

Sara Llufriu, Pablo Villoslada, Magi Andorra, 2018, PloS one.

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine

I. Zubizarreta, I. Pulido-Valdeolivas, P. Villoslada, 2018, Therapeutic advances in neurological disorders.

Visual field impairment captures disease burden in multiple sclerosis

I. Zubizarreta, P. Villoslada, M. Andorrà, 2016, Journal of Neurology.

Impairment of decision-making in multiple sclerosis: A neuroeconomic approach

Dino J. Levy, P. Glimcher, I. Zubizarreta, 2017, Multiple sclerosis.

The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS

I. Zubizarreta, P. Villoslada, E. Martínez-Heras, 2014, BMC Research Notes.